Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In breast cancer, overexpression of the transmembrane tyrosine kinase ERBB2 is an adverse prognostic marker, and occurs in almost 30% of the patients. For therapeutic intervention, ERBB2 is targeted by monoclonal antibody trastuzumab in adjuvant settings; however, de novo resistance to this antibody is still a serious issue, requiring the identification of additional targets to overcome resistance. In this study, we have combined computational simulations, experimental testing of simulation results, and finally reverse engineering of a protein interaction network to define potential therapeutic strategies for de novo trastuzumab resistant breast cancer. RESULTS: First, we employed Boolean logic to model regulatory interactions and simulated single and multiple protein loss-of-functions. Then, our simulation results were tested experimentally by producing single and double knockdowns of the network components and measuring their effects on G1/S transition during cell cycle progression. Combinatorial targeting of ERBB2 and EGFR did not affect the response to trastuzumab in de novo resistant cells, which might be due to decoupling of receptor activation and cell cycle progression. Furthermore, examination of c-MYC in resistant as well as in sensitive cell lines, using a specific chemical inhibitor of c-MYC (alone or in combination with trastuzumab), demonstrated that both trastuzumab sensitive and resistant cells responded to c-MYC perturbation. CONCLUSION: In this study, we connected ERBB signaling with G1/S transition of the cell cycle via two major cell signaling pathways and two key transcription factors, to model an interaction network that allows for the identification of novel targets in the treatment of trastuzumab resistant breast cancer. Applying this new strategy, we found that, in contrast to trastuzumab sensitive breast cancer cells, combinatorial targeting of ERBB receptors or of key signaling intermediates does not have potential for treatment of de novo trastuzumab resistant cells. Instead, c-MYC was identified as a novel potential target protein in breast cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“Trastuzumab is administrated to ERBB2-overexpressing breast cancer patients [8,9].”
BackgroundTrastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
The regulation of E2F by pRB-family proteins.
Dyson, N. (1998) · Genes & Development · doi:10.1101/gad.12.15.2245 · Cited by 2,317
EGF–ERBB signalling: towards the systems level
Citri, A., & Yarden, Y. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1962 · Cited by 2,004
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F., & Rolfe, M. (1995) · Science · doi:10.1126/science.7624798 · Cited by 1,817
Yıldırım, M. A., Goh, K.-I., Cusick, M. E., Barabási, A.-L., & Vidal, M. (2007) · Nature Biotechnology · doi:10.1038/nbt1338 · Cited by 1,708
G1 cell-cycle control and cancer
Massagué, J. (2004) · Nature · doi:10.1038/nature03094 · Cited by 1,224
Harbour, J. W., Luo, R. X., Santi, A. D., Postigo, A. A., & Dean, D. C. (1999) · Cell · doi:10.1016/s0092-8674(00)81519-6 · Cited by 1,057
Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.
Guy, P. M., Platko, J. V., Cantley, L. C., Cerione, R. A., & Carraway, K. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.17.8132 · Cited by 698
Dynamical analysis of a generic Boolean model for the control of the mammalian cell cycle
Fauré, A., Naldi, A., Chaouiya, C., & Thieffry, D. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl210 · Cited by 642
Self-citationThe ErbB receptors and their role in cancer progression
Holbro, T. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00099-x · Cited by 608
Knowlden, J. M., Hutcheson, I. R., Jones, H. E., Madden, T., Gee, J. M. W., Harper, M. E., Barrow, D., Wakeling, A. E., & Nicholson, R. I. (2003) · Endocrinology · doi:10.1210/en.2002-220620 · Cited by 521
Proliferation of cancer cells despite CDK2 inhibition
Tetsu, O., & McCormick, F. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00053-9 · Cited by 466
Klapper, L. N., Glathe, S., Vaisman, N., Hynes, N. E., Andrews, G. C., Sela, M., & Yarden, Y. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.4995 · Cited by 455 · cited 1×
“ERBB2, the main player of the ERBB network, does not show any ligand binding activity, but has high dimerization affinity [5,6].”
BackgroundHerceptin: mechanisms of action and resistance
Nahta, R., & Esteva, F. J. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.01.041 · Cited by 446
Signal transduction and oncogenesis by ErbB/HER receptors
Marmor, M. D., Skaria, K. B., & Yarden, Y. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.06.002 · Cited by 389 · cited 1×
“The ERBB family of receptor tyrosine kinases is composed of four receptors that have the ability to form homo- and heterodimers, and couple binding of extracellular growth factors to intracellular signal transduction pathways [3,4].”
BackgroundA model for restriction point control of the mammalian cell cycle
Novák, B., & Tyson, J. J. (2004) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2004.04.039 · Cited by 305
P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells
Nahta, R., Takahashi, T., Ueno, N. T., Hung, M.-C., & Esteva, F. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3900 · Cited by 298 · cited 1×
“Interestingly, the five novel candidates to be targeted in de novo trastuzumab resistant breast cancer have one feature in common: they all either directly (ER-α, c-MYC and CDK4) or indirectly (Cyclin D1 and Cyclin E1) regulate the p27 protein, which plays a key role also in acquired trastuzumab resistance [38].”
BackgroundLane, H. A., Beuvink, I., Motoyama, A. B., Daly, J. M., Neve, R. M., & Hynes, N. E. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.9.3210-3223.2000 · Cited by 298
The complexity of targeting EGFR signalling in cancer: From expression to turnover
Sebastian, S., Settleman, J., Reshkin, S. J., Azzariti, A., Bellizzi, A., & Paradiso, A. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.06.001 · Cited by 260
Recent Trends in Targeted Anticancer Prodrug and Conjugate Design
Singh, Y., Palombo, M., & Sinko, P. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708785132997 · Cited by 242
Ligand‐dependent responses of the ErbB signaling network: experimental and modeling analyses
Birtwistle, M. R., Hatakeyama, M., Yumoto, N., Ogunnaike, B. A., Hoek, J. B., & Kholodenko, B. N. (2007) · Molecular Systems Biology · doi:10.1038/msb4100188 · Cited by 234
Gee, J. M., Robertson, J. F., Gutteridge, E., Ellis, I. O., Pinder, S. E., Rubini, M., & Nicholson, R. I. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.01005 · Cited by 209
Gonzalez, A. G., Naldi, A., Sánchez, L., Thieffry, D., & Chaouiya, C. (2006) · Biosystems · doi:10.1016/j.biosystems.2005.10.003 · Cited by 194
Self-citationLe, X., Pruefer, F., & Bast, R. C. (2004) · Cell Cycle · doi:10.4161/cc.4.1.1360 · Cited by 170
Amit, I., Wides, R., & Yarden, Y. (2007) · Molecular Systems Biology · doi:10.1038/msb4100195 · Cited by 142
Zaczek, A. J., Brandt, B., & Bielawski, K. P. (2005) · PubMed · doi:10.14670/hh-20.1005 · Cited by 127
Takahashi‐Yanaga, F., Taba, Y., Miwa, Y., Kubohara, Y., Watanabe, Y., Hirata, M., Morimoto, S., & Sasaguri, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m205768200 · Cited by 116
Infrared‐based protein detection arrays for quantitative proteomics
Löbke, C., Sueltmann, H., Schmidt, C., Henjes, F., Wiemann, S., Poustka, A., & Korf, U. (2007) · PROTEOMICS · doi:10.1002/pmic.200600757 · Cited by 100
Self-citationGrillo, M., Bott, M. J., Khandke, N., McGinnis, J. P., Miranda, M., Meyyappan, M., Rosfjord, E. C., & Rabindran, S. K. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9066-y · Cited by 90
Modulation of pRb/E2F Functions in the Regulation of Cell Cycle and in Cancer
Seville, L., Shah, N., Westwell, A. D., & Chan, W. C. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053765816 · Cited by 82
Park, K., Kwak, K., Kim, J., Lim, S., & Han, S. (2005) · Human Pathology · doi:10.1016/j.humpath.2005.04.016 · Cited by 71
A systems biology dynamical model of mammalian G 1 cell cycle progression
Haberichter, T., Mädge, B., Christopher, R. A., Yoshioka, N., Dhiman, A., Miller, R., Gendelman, R., Aksenov, S. V., Khalil, I. G., & Dowdy, S. F. (2007) · Molecular Systems Biology · doi:10.1038/msb4100126 · Cited by 62
Combinatorial RNAi for quantitative protein network analysis
Şahin, Ö., Löbke, C., Korf, U., Appelhans, H., Sültmann, H., Poustka, A., Wiemann, S., & Arlt, D. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606827104 · Cited by 55
Self-citationSystems biology approach to identification of biomarkers for metastatic progression in cancer
Ptitsyn, A. A., Weil, M. M., & Thamm, D. H. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-s9-s8 · Cited by 45
Piccart, M. (2008) · Clinical Breast Cancer · doi:10.3816/cbc.2008.s.006 · Cited by 42
Cited by
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
Kinase-targeted cancer therapies: progress, challenges and future directions
Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0804-2 · Cited by 1,245
Cancer systems biology: a network modeling perspective
Kreeger, P. K., & Lauffenburger, D. A. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp261 · Cited by 368
Logic-Based Models for the Analysis of Cell Signaling Networks
Morris, M. K., Saez-Rodriguez, J., Sorger, P. K., & Lauffenburger, D. A. (2010) · Biochemistry · doi:10.1021/bi902202q · Cited by 332
Breslin, S., & O’Driscoll, L. (2016) · Oncotarget · doi:10.18632/oncotarget.9935 · Cited by 311
Metadata
- Authors
- Sahin, Ö., Fröhlich, H., Löbke, C., Korf, U., Burmester, S., Majety, M., Mattern, J., Schupp, I., Chaouiya, C., Thieffry, D., Poustka, A., Wiemann, S., Beissbarth, T., & Arlt, D.
- Venue
- BMC Systems Biology
- Published
- 2009-01-01
- Volume
- 3
- Issue
- 1
- Pages
- 1-1
- ISSN
- 1752-0509 (ISSN-L)
- OpenAlex
- W2042459594
- Cited by
- 335
- References
- 39
- FWCI
- 10.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.